Orforglipron for Weight Loss: What the Evidence Shows
What human and animal studies show about Orforglipron for weight loss, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 55
- PubMed records, our ledger
- Animal studies
- 0
- PubMed records, our ledger
- Studies we summarised
- 9
- with an outcome for weight loss
Evidence for weight loss
Each row is an outcome related to weight loss from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body weight change | In people with diabetes, bodyweight changed by -5·1% (6 mg), -7·0% (12 mg) and -9·6% (36 mg) with orforglipron vs -2·5% with placebo at week 72. | Human RCTn = 1613 | Lancet 2026, PMID 41275875 |
| Maintenance of weight reduction after tirzepatide | After prior tirzepatide, orforglipron maintained an estimated 74.7% of body weight reduction vs 49.2% with placebo. | Human RCTn = 376 | Nature medicine 2026, PMID 42120723 |
| Maintenance of weight reduction after semaglutide | After prior semaglutide, orforglipron maintained an estimated 79.3% of body weight reduction vs 37.6% with placebo. | Human RCTn = 376 | Nature medicine 2026, PMID 42120723 |
| Weight change in older adults | In older adults without diabetes, weight changed by -7.9%, -11.3% and -13.0% with orforglipron vs -1.6% with placebo at week 72. | Human RCTn = 616 | Obesity pillars 2026, PMID 42577069 |
| Body weight change | Body weight changed by -7.5% (6 mg), -8.4% (12 mg) and -11.2% (36 mg) with orforglipron vs -2.1% with placebo at week 72. | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Weight reduction thresholds at highest dose | In the 36-mg group, 54.6%, 36.0% and 18.4% lost at least 10%, 15% and 20% of body weight, vs 12.9%, 5.9% and 2.8% on placebo. | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Cardiometabolic measures | Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol significantly improved versus placebo. | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Body weight | Body weight changed by -4.5%, -5.8% and -7.6% (3, 12, 36 mg) vs -1.7% with placebo. | Human RCTn = 559 | The New England journal of medicine 2025, PMID 40544435 |
| Body weight change | Body weight changed by -8.6% to -12.6% at week 26 and -9.4% to -14.7% at week 36 with orforglipron, vs -2.0% and -2.3% with placebo. | Human RCTn = 272 | The New England journal of medicine 2023, PMID 37351564 |
| Short-term weight change | Body weight fell by up to 5.4 kg after 4 weeks with orforglipron vs 2.4 kg with placebo. | Human RCTn = 92 | Diabetes, obesity & metabolism 2023, PMID 37344954 |
| Glycated hemoglobin and weight | Glycated hemoglobin changed by -1.5% to -1.8% with orforglipron vs -0.4% with placebo; body weight changed by -0.24 to -5.8 kg vs 0.5 kg. | Human RCTn = 68 | Diabetes, obesity & metabolism 2023, PMID 37264711 |
| Weight loss | Versus placebo, orforglipron reduced body weight by 6.14 kg and waist circumference by 5.32 cm. | Meta-analysisn = 815 | Archives of endocrinology and metabolism 2024, PMID 39420937 |
PubMed records for Orforglipron and weight loss: 55 human, 0 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for weight loss
All peptides for weight loss, comparedCommon questions
Does Orforglipron help with weight loss?
The strongest study we summarise for weight loss is human rct evidence, across 9 studies with an outcome for weight loss. A trial result is not an approval; see the legal status.
Is Orforglipron approved for weight loss?
Orforglipron is FDA approved (Foundayo, Apr 2026). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for weight loss?
There is no single answer. Our weight loss overview compares each candidate by evidence grade and legal status rather than by popularity.
More on Orforglipron
DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.
Sources
- 1Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 2Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
- 3Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
- 4Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 5Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
- 6Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
- 7Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
- 8Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
- 9Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.Archives of endocrinology and metabolism · 2024PMID 39420937Accessed 2 Oct 2026
Found an error? Report a correction.